Coghlan JG, et al. - Researchers performed a post hoc analysis of the phase III GRIPHON trial, wherein, they assessed the efficacy and safety of selexipag as a third agent in patients with pulmonary arterial hypertension (PAH), including those receiving background double combination therapy. They also further analyzed this subgroup according to symptom burden at baseline as indicated by World Health Organization (WHO) functional class (FC). Findings demonstrated an incremental benefit afforded by adding selexipag to background double combination therapy with an endothelin receptor antagonist (ERA) and phosphodiesterase-5 inhibitor (PDE-5i). This incremental benefit was found to be similar to that seen in the overall population, including in patients with WHO FC II or III symptoms at baseline.